Pharmaceuticals

Next-Gen Epkinly: Market Forecast, Transformation, and Long-Term Trajectories

June 24, 2025 by Marketing Posting

Discover trends, market shifts, and competitive outlooks for the epkinly global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Projected Market Size and Growth Rates for the Epkinly Market From 2025 To 2029?#_x000D_

In the recent past, the epkinly market has expanded by XX (HCAGR). The market, which was worth $XX million in 2024, is projected to increase to $XX million in 2025, growing at a compound annual growth rate (CAGR) of XX%. The historic development is ascribed to factors including enhanced awareness about healthcare, greater support through regulations, a particularly susceptible pediatric demographic, and a rise in the frequency of cancer, particularly lung cancer._x000D_

_x000D_

Forecasts anticipate that the epkinly market will experience an XX (FCAGR) increase in the coming years, culminating in a value of $XX million in 2029 with an XX% compound annual growth rate (CAGR). The predicted market expansion during this period can be credited to an escalation in research and development efforts, growing utilization of advanced therapies, an increase in health consciousness, augmented investment, and enhanced employment of innovative treatments. The period will likely be characterized by significant occurrences including the introduction of new drugs, escalated research and development endeavors for non-Hodgkin lymphoma treatments, unique treatment possibilities, cutting-edge technological progression, and innovative enhancements._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20060&type=smp_x000D_

_x000D_

#Which Major Market Drivers Are Expected to Boost the Growth Potential of the Epkinly Market?#_x000D_

The surge in demand for targeted treatments is projected to fuel the growth of the epkinly market in the future. These specific therapies obstruct molecules that trigger diseases, particularly cancers, offering fewer side effects than conventional treatments. Their popularity is on the rise, owing to their potential to produce more efficient, personalized treatments that are associated with fewer side effects. Epcoritamab, marketed as epkinly, is employed in targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. It works by binding CD3 on T cells and CD20 on B cells, compelling the immune system to obliterate the cancerous B cells. For example, in October 2024, the UK-based National Health Service reported that, in 2023/24, 14.5% of hormone replacement therapy items were linked with an HRT prescription prepayment certificate. By June 2024, this percentage had escalated to 21%, a significant increase from 9.7% in June 2023. Therefore, the escalating demand for targeted treatments is fuelling the expansion of the epkinly market._x000D_

_x000D_

#Which Key Market Segments Comprise the Epkinly Market and Drive Its Revenue Growth?#_x000D_

The epkinly market covered in this report is segmented –_x000D_

_x000D_

1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma_x000D_

2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20060&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Epkinly Market Expansion Across the Globe?#_x000D_

North America was the largest region in the epkinly market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#What Are the Key Market Trends in the Epkinly Market Over the Coming Years?#_x000D_

Key developments in the epkinly market comprise securing regulatory authorizations for groundbreaking therapies like bispecific antibody therapies, to bolster treatment outcomes and diversify therapeutic prospects. Bispecific antibody therapies are a distinct type of immunotherapy that utilizes antibodies engineered to simultaneously latch onto two distinct antigens or targets. As an example, in June 2024, the American biotech firm AbbVie Inc. achieved FDA approval for EPKINLY (epcoritamab-bysp), which is the first bispecific antibody for adults suffering from relapsed or refractory follicular lymphoma (FL) having undertaken two or more rounds of systemic therapy. This trailblazing treatment employs the immune system by aligning with CD20 and CD3, resulting in a remarkable overall response rate of 82% in clinical trials. Delivered subcutaneously in a phosphorescent dosing regimen, EPKINLY represents a fresh potentiality for patients with scant alternatives. This sanction signifies a substantial progress in the treatment of follicular lymphoma and offers promising potential for better patient outcomes._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/epkinly-global-market-report_x000D_

_x000D_

#How Is the Epkinly Market Conceptually Defined?#_x000D_

Epkinly (also known by its generic name epcoritamab) is a monoclonal antibody used in the treatment of certain types of cancer, particularly relapsed or refractory B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphoma (NHL) subtypes. It works by targeting and binding to CD3, a protein found on T cells, and CD20, a protein found on B cells, which helps the immune system recognize and destroy cancerous cells._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20060_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_